PubMed:26937641 / 1074-1213
Annnotations
LitCoin-entities
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
11134 | 17-37 | DiseaseOrPhenotypicFeature | denotes | hepatic fibrogenesis | MESH:D008107 |
11135 | 39-43 | GeneOrGeneProduct | denotes | CCl4 | NCBIGene:6351 |
11136 | 101-105 | GeneOrGeneProduct | denotes | SAA1 | NCBIGene:20208 |
11137 | 110-114 | GeneOrGeneProduct | denotes | SAA3 | NCBIGene:20210 |
LitCoin-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T10 | 0-139 | Sentence | denotes | In two models of hepatic fibrogenesis, CCl4 treatment and bile duct ligation, hepatic mRNA levels of SAA1 and SAA3 were strongly increased. |
LitCoin_Mondo
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T4 | 17-24 | DiseaseOrPhenotypicFeature | denotes | hepatic | 0002251 |
T5 | 78-85 | DiseaseOrPhenotypicFeature | denotes | hepatic | 0002251 |
LitCoin-GeneOrGeneProduct-v0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T44 | 39-43 | GeneOrGeneProduct | denotes | CCl4 |
T45 | 86-90 | GeneOrGeneProduct | denotes | mRNA |
T46 | 101-105 | GeneOrGeneProduct | denotes | SAA1 |
T47 | 110-114 | GeneOrGeneProduct | denotes | SAA3 |
LitCoin-GeneOrGeneProduct-v2
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T28 | 86-90 | GeneOrGeneProduct | denotes | mRNA |
T29 | 101-105 | GeneOrGeneProduct | denotes | SAA1 |
T30 | 110-114 | GeneOrGeneProduct | denotes | SAA3 |
LitCoin-GeneOrGeneProduct-v3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T21 | 101-105 | GeneOrGeneProduct | denotes | SAA1 |
T22 | 110-114 | GeneOrGeneProduct | denotes | SAA3 |
LitCoin-MeSH-Disease-2
Id | Subject | Object | Predicate | Lexical cue | ID: |
---|---|---|---|---|---|
T7 | 17-37 | DiseaseOrPhenotypicFeature | denotes | hepatic fibrogenesis | DISEASE |
LitCoin-MONDO_bioort2019
Id | Subject | Object | Predicate | Lexical cue | #label |
---|---|---|---|---|---|
T3 | 17-37 | DiseaseOrPhenotypicFeature | denotes | hepatic fibrogenesis | DISEASE |
LitCoin-Chemical-MeSH-CHEBI
Id | Subject | Object | Predicate | Lexical cue | ID: |
---|---|---|---|---|---|
T5 | 39-43 | ChemicalEntity | denotes | CCl4 | http://purl.obolibrary.org/obo/CHEBI_27385 |
LitCoin-training-merged
Id | Subject | Object | Predicate | Lexical cue | #label | ID: |
---|---|---|---|---|---|---|
T5 | 39-43 | ChemicalEntity | denotes | CCl4 | http://purl.obolibrary.org/obo/CHEBI_27385 | |
T22 | 110-114 | GeneOrGeneProduct | denotes | SAA3 | ||
T21 | 101-105 | GeneOrGeneProduct | denotes | SAA1 | ||
T29613 | 17-37 | DiseaseOrPhenotypicFeature | denotes | hepatic fibrogenesis | DISEASE |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T10 | 0-139 | Sentence | denotes | In two models of hepatic fibrogenesis, CCl4 treatment and bile duct ligation, hepatic mRNA levels of SAA1 and SAA3 were strongly increased. |
T10 | 0-139 | Sentence | denotes | In two models of hepatic fibrogenesis, CCl4 treatment and bile duct ligation, hepatic mRNA levels of SAA1 and SAA3 were strongly increased. |